Welcome to our dedicated page for Radnet news (Ticker: RDNT), a resource for investors and traders seeking the latest updates and insights on Radnet stock.
RadNet, Inc. (NASDAQ: RDNT) generates a steady flow of news as a national provider of freestanding, fixed-site diagnostic imaging services and as the parent of DeepHealth, its AI-powered health informatics division. News about RadNet often highlights developments across its network of 407 owned and/or operated outpatient imaging centers in markets such as Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas, as well as updates from its Digital Health segment.
Investors and observers following RDNT news will encounter announcements on topics such as acquisitions of imaging centers, expansion into new regional markets and updates on RadNet’s operational performance. For example, the company has reported acquisitions like Radiology Regional in Southwest Florida, adding multiple imaging centers and staff to its Florida footprint. Earnings releases and financial guidance updates are also frequent news items, reflecting trends in imaging volumes, segment revenue and Adjusted EBITDA for both the Imaging Center and Digital Health segments.
RadNet’s DeepHealth division is another major source of news, with press releases covering the launch of AI-powered clinical suites, imaging informatics platforms and collaborations with partners. Recent communications have described products such as Breast Suite, Thyroid Suite, Operations Suite, Diagnostic Suite and TechLive, as well as research findings published in scientific journals and showcased at industry conferences like RSNA. News may also cover strategic collaborations, including letters of intent and partnerships with companies such as GE HealthCare to expand AI-powered imaging solutions across modalities and geographies.
Because RadNet regularly issues updates on its financial results, acquisitions, digital health initiatives and research milestones, the RDNT news page can be a useful resource for tracking how the company’s imaging center operations and DeepHealth portfolio evolve over time. Readers interested in diagnostic imaging services, AI in radiology and healthcare operations technology may find RadNet’s news particularly relevant.
RadNet (NASDAQ: RDNT) reported a quarterly record $547.7M revenue and $87.7M Adjusted EBITDA for Q4 2025, increases of 14.8% and 16.9% year-over-year respectively. Full-year 2025 revenue was $2,040.2M with Adjusted EBITDA of $300.2M.
The company reported strong advanced imaging volume growth, Digital Health momentum (Q4 revenue $27.9M), the Gleamer acquisition, and 2026 guidance calling for double-digit revenue and EBITDA growth across segments.
RadNet (NASDAQ: RDNT) acquired Paris-based Gleamer for up to €230 million, integrating it into DeepHealth to create the world’s largest provider of radiology clinical AI solutions.
Gleamer brings ~130 staff, >700 customer contracts in 44 countries, four FDA-cleared and six CE-marked devices, and an expected $30M ARR in 2026 after >90% ARR CAGR (2022–2025). Deployment across RadNet aims for cost and productivity gains by Q3 2026, with focus on X-ray (≈25% of RadNet volume).
DeepHealth (NASDAQ: RDNT) announced that TechLive achieved CE marking on Feb 26, 2026 and is now listed in AWS Marketplace, enabling European commercialization and faster global deployments. TechLive supports MR, CT, PET/CT and ultrasound and is vendor‑agnostic.
Within RadNet, TechLive has connected more than 400 scanners, with reported improvements including a 42% reduction in MR room closure hours and a 27% increase in access to complex procedures. DeepHealth will showcase TechLive at ECR 2026, March 4-8 in Vienna (Booth 506, X5).
RadNet (NASDAQ: RDNT) will host a conference call to discuss its fourth quarter 2025 financial results on Monday, March 2, 2026 at 7:30 a.m. PT / 10:30 a.m. ET. Investors can join by phone or via a simultaneous webcast.
Dial 844-826-3035 (U.S.) or 412-317-5195 (international). Webcast and archived replay details, including replay dial numbers and passcode 10206844, are provided for investor access.
RadNet (NASDAQ: RDNT) acquired the outpatient imaging assets of Northwest Radiology Network, adding six multimodality centers in greater Indianapolis and establishing RadNet's entry into Indiana and the Midwest.
The deal preserves contracted services with 18 Northwest radiologists and is projected to add approximately $18 million of annualized revenue.
RadNet (NASDAQ: RDNT) will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST at The Westin St. Francis Hotel in San Francisco. Presenters include Dr. Howard Berger (President & CEO), Mark Stolper (EVP & CFO), Dr. Gregory Sorensen (EVP & Chief Strategy Officer) and Kees Wesdorp (President & CEO, RadNet Digital Health).
A live webcast is available and offered for replay at the conference webcast link; the company is a national diagnostic imaging provider with 407 owned/operated outpatient imaging centers and over 11,000 team members.
RadNet (NASDAQ: RDNT) has acquired Radiology Regional from LucidHealth, adding 13 imaging centers across Southwest Florida (Naples, Cape Coral, Fort Myers, Port Charlotte, Sarasota).
The deal brings an estimated 400 employees, 44 contracted radiologists and is projected to add approximately $100 million of revenue to RadNet in 2026. Services include MRI, CT, PET/CT, mammography, ultrasound and X-ray.
RadNet said it will deploy its DeepHealth AI portfolio and operational processes to expand access, screening programs and clinical accuracy in the acquired centers.
RadNet (NASDAQ: RDNT) announced the promotion of four senior leaders to expanded executive roles effective January 7, 2026. The changes elevate Stephen Forthuber to President & CEO, Eastern Operations, Norman Hames to President & CEO, Western Operations, Mital Patel to Executive VP & Chief Operating Officer, and Greg Sorensen, M.D., from Chief Science Officer to Chief Strategy Officer while remaining on RadNet’s board.
Company commentary ties the moves to recent record performance across Imaging Center and Digital Health segments and to a strategic focus on moving healthcare toward proactive disease prevention.
DeepHealth (Nasdaq: RDNT) launched Breast Suite on Dec 1, 2025, an AI-powered, modular platform for breast cancer screening, detection, risk stratification and workflow.
Key clinical validations include a 21% increase in cancer detection across >579,000 women, 23% more cancers detected in dense breasts, and 20% more cancers detected in Black, non-Hispanic women. The suite supports >10 million mammograms annually and integrates detection, automated density, a mammogram-calibrated risk model (reported as 2x accuracy vs questionnaire models), cloud viewing, prioritized worklists and intelligent reporting.
DeepHealth (Nasdaq: RDNT) unveiled an expanded portfolio of imaging informatics and clinical AI solutions at RSNA 2025 on November 30, 2025. The announcement highlights integrations across Diagnostic Suite, TechLive, Operations Suite and modality-specific Clinical AI suites (Breast, Thyroid, Neuro, Chest, Prostate) running on DeepHealth OS to unify imaging workflows, reporting and AI orchestration.
Notable disclosed impacts include 400+ scanners connected to TechLive, 42% fewer MR room closures, support for > 10 million mammograms annually, a Nature Health analysis showing 21% higher breast cancer detection in 579,000 women, deployment at > 200 sites for Thyroid Suite, and > 2,000 customers with 5,000+ radiologists using DeepHealth solutions.